IsoRay Announces Greek Governmental Approval for Sales of Its Entire Product Line
March 11 2014 - 9:30AM
Marketwired
IsoRay Announces Greek Governmental Approval for Sales of Its
Entire Product Line
IsoRay's Distributor IASIS MEDICAL Sees Large Opportunities in
Greece for IsoRay's Products
RICHLAND, WA--(Marketwired - Mar 11, 2014) - IsoRay, Inc.
(NYSEMKT: ISR) (http://www.isoray.com/), announced today that IASIS
Medical has received formal approval for the sale of IsoRay's
complete product line in Greece. IsoRay is a medical technology
company and innovator in seed brachytherapy and medical
radioisotope applications for brain cancer, lung cancer, head and
neck cancer, prostate cancer and gynecologic ("gyn") cancer.
IASIS Medical is ideally suited to support IsoRay's products,
which utilize the uniqueness of our Cesium-131 isotope to attack
cancers in the prostate and other body sites, such as brain cancer,
head and neck cancer, lung cancer and gyn cancers. Furthermore
citizens of Greece residing on islands and non-metropolitan areas
will have more access to localized care, while providing patients
with a better quality of life than many competing treatments.
Internationally IsoRay is obtaining increasing recognition in the
world marketplace for cancer treatments as more physicians and
surgeons are made aware of the power of Cesium-131through
posters/abstracts at conventions and soon to be published
studies.
IsoRay Chairman and CEO Dwight Babcock commented, "We are very
optimistic about the unique opportunities for growth in Greece for
our expanding product line and look to the international market to
contribute in the future of IsoRay's profitability. IsoRay's
products currently carry FDA clearance and the CE Mark, making them
eligible to be sold in 31 European nations. Physicians and
institutions throughout the US are continuing to report outstanding
results in the use of our Cs-131 seeds for brain cancer, head and
neck cancer, prostate cancer and lung cancers. As peer reviewed
papers are released we anticipate a growing acceptance and interest
in our products. We remain committed to our strategic national and
international marketing objectives and believe this will contribute
to our long term success and shareholder value."
About IsoRay IsoRay, Inc., through its subsidiary, IsoRay
Medical, Inc. is the sole producer of Cesium-131 brachytherapy
seeds, which is expanding brachytherapy options throughout the
body. Learn more about this innovative Richland, Washington company
and explore the many benefits and uses of GliaSite® and Cesium-131
by visiting www.isoray.com. Join us on Facebook/Isoray. Follow us
on Twitter@Isoray.
Safe Harbor Statement Statements in this news release about
IsoRay's future expectations, including: the advantages of our
Cesium-131 seed, future demand for IsoRay's existing and planned
products, whether regulatory approvals and licenses will be
obtained or maintained in foreign countries, whether IsoRay will be
able to continue to expand its base beyond prostate cancer, whether
IsoRay will be able to generate sales in the U.S. and
internationally, whether additional studies will be published with
favorable outcomes from treatment with Cesium-131, whether IsoRay's
sales and marketing and research and development efforts will
contribute to growth, whether new products will be developed and if
so whether they will be adopted by physicians, and all other
statements in this release, other than historical facts, are
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995 ("PSLRA"). This statement
is included for the express purpose of availing IsoRay, Inc. of the
protections of the safe harbor provisions of the PSLRA. It is
important to note that actual results and ultimate corporate
actions could differ materially from those in such forward-looking
statements based on such factors as physician acceptance, training
and use of IsoRay's products, changing levels of demand for
IsoRay's current and proposed future products, whether later
studies and protocols support the findings of the initial studies,
success of future research and development activities, patient
results achieved when Cesium-131 is used for the treatment of
cancers and malignant diseases beyond prostate cancer, IsoRay's
ability to successfully manufacture, market and sell its products,
whether institutions will receive all required state, federal and
foreign regulatory approvals and licenses to use IsoRay's products,
IsoRay's ability to manufacture its products in sufficient
quantities to meet demand within required delivery time periods
while meeting its quality control standards, IsoRay's ability to
enforce its intellectual property rights, changes in reimbursement
rates, changes in laws and regulations applicable to our products,
and other risks detailed from time to time in IsoRay's reports
filed with the SEC.
Contact: IsoRay Medical (509) 375-1202
Info@Isoray.com.com
IsoRay (AMEX:ISR)
Historical Stock Chart
From May 2024 to Jun 2024
IsoRay (AMEX:ISR)
Historical Stock Chart
From Jun 2023 to Jun 2024